The first HER2-targeted drug, trastuzumab, can significantly improve the prognosis of patients with HER2-positive breast cancer; however, some patients will relapse due to drug resistance or insufficient immune response, for instance, the low activity of NK cell-mediated ADCC. Here, ERBB2 is linked to breast carcinoma.